Avalyn Pharma director granted 26,978 stock options

Avalyn Pharma Inc. director Heather D. Turner received a compensation grant of stock options covering 26,978 shares of common stock.

Rhea-AI Filing Summary

Avalyn Pharma Inc. director Heather D. Turner received a compensation grant of stock options covering 26,978 shares of common stock. The options have an exercise price of $18.00 per share and expire on April 28, 2036.

According to the vesting terms, 25% of the shares vest and become exercisable on September 12, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to her continued service. Following this grant, Turner holds stock options for 26,978 underlying shares directly.

Insider Trade Summary

Grant/Award: 26,978 shares

Grant/Award 1 txn

Insider Turner Heather D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	26,978	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 26,978 contracts (Direct)

Footnotes (1)

1. F1. 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Options granted: 26,978 options Exercise price: $18.00 per share Underlying shares: 26,978 shares +4 more

7 metrics

Options granted 26,978 options Stock Option (Right to Buy) grant to director

Exercise price $18.00 per share Strike price for the stock options

Underlying shares 26,978 shares Common stock underlying granted options

Post-grant option holdings 26,978 options Total options held following transaction

Initial vesting date September 12, 2025 25% of options vest on this date

Remaining vesting schedule 36 monthly installments Remaining 75% vests over 36 months

Option expiration April 28, 2036 Expiration date of the stock options

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 18.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"25% of the shares underlying this option vest and become exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-04-28"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Heather D. Turner report for AVLN?

Heather D. Turner reported receiving a grant of stock options for 26,978 shares of Avalyn Pharma common stock. These options are a compensation award, not an open-market purchase, and give her the right to buy shares at a fixed exercise price.

What is the exercise price of Heather D. Turner’s Avalyn Pharma options?

The granted stock options have an exercise price of $18.00 per share. This means Turner can later buy Avalyn Pharma common stock at $18.00, regardless of the future market price, once the options have vested.

How do Heather D. Turner’s AVLN stock options vest over time?

Twenty-five percent of the options vest on September 12, 2025. The remaining 75% vest in 36 equal monthly installments afterward, contingent on Turner’s continued service, creating a multi-year incentive structure aligned with ongoing board participation.

When do Heather D. Turner’s Avalyn Pharma options expire?

The stock options granted to Heather D. Turner expire on April 28, 2036. After that date, any unexercised options will lapse, so the potential right to buy Avalyn Pharma shares at $18.00 ends on that expiration date.

How many Avalyn Pharma shares are covered by Heather D. Turner’s options after this grant?

Following this grant, Turner holds stock options covering 26,978 underlying shares of Avalyn Pharma common stock. All of these options were acquired in this single award and are held directly in her name according to the filing.

Is Heather D. Turner’s AVLN transaction a buy or a sale of shares?

The transaction is classified as a grant or award acquisition of stock options, not a market buy or sale of common shares. No open-market purchase or sale occurred; the company awarded derivative securities as part of compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 06:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Turner Heather D

(Last) (First) (Middle)

C/O AVALYN PHARMA INC.

105 W FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalyn Pharma Inc. [ AVLN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18	04/29/2026		A		26,978		(1)	04/28/2036	Common Stock	26,978	$0.00	26,978	D

Explanation of Responses:

1. 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Douglas Carlson	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)